subunit recombinant vaccine for the prevention of coronavirus infection
VaccineexperimentalCOVID-19
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jul 19, 2021 (NCT05156723)
Timeline
Indications
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05726084 | Phase 2/Phase 3 (Phase 3) | Oct 24, 2022 | St. Petersburg Research Institute of Vaccines and Sera |
| NCT05156723 | Phase 1/Phase 2 (Phase 2) | Jul 19, 2021 | Crocus Medical BV, St. Petersburg Research Institute of Vaccines and Sera |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| St. Petersburg Research Institute of Vaccines and Sera | Academic/Hospital | 2 | 2 | 2 | 2021 |
| Crocus Medical BV | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1